A Phase II, Multicentre, Open-label Study of Cabozantinib as 2nd Line Treatment in Subjects With Unresectable, Locally Advanced or Metastatic Renal Cell Carcinoma With a Clear-Cell Component Who Progressed After 1st Line Treatment With Checkpoint Inhibitors
Latest Information Update: 10 Mar 2025
At a glance
- Drugs Cabozantinib (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- Acronyms CABOPOINT; CaboPoint
- Sponsors Ipsen
Most Recent Events
- 07 Mar 2025 Planned End Date changed from 30 Sep 2099 to 30 Dec 2030.
- 29 Mar 2024 Planned End Date changed from 14 Nov 2024 to 30 Sep 2099.
- 22 Feb 2024 Planned End Date changed from 14 Dec 2023 to 14 Nov 2024.